Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice

Vaccine

Volumn 28, Issue 5, 2010, Pages 1193-1200

  Del Campo, Judith ^a   Lindqvist, Madelene ^b   Cuello, Maribel ^a   Bäckström, Malin ^c   Cabrerra, Osmir ^a   Persson, Josefine ^b   Perez, Oliver ^a   Harandi, Ali M ^b  

^a FINLAY INSTITUTE   (Cuba)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Department of Medical Biochemistry and Cell Biology   (Sweden)

Author keywords

Adjuvant; Genital herpes; Mucosal immunity; Mucosal vaccine; Sexually transmitted infections; Toll like receptor

Indexed keywords

ADJUVANT; ADJUVANT FINLAY PROTEOLIPOSOME 1; ADJUVANT FINLAY PROTEOLIPOSOME 1 DERIVED COCHLEATE; GAMMA INTERFERON; GLYCOPROTEIN D; HERPES VACCINE; IMMUNOGLOBULIN G; MYELOID DIFFERENTIATION FACTOR 88; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEOLIPOSOME; SPLEEN CELL; VIRUS IMMUNITY;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LIPOSOMES; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NEISSERIA MENINGITIDIS, SEROGROUP B; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS;

EID: 74249104167     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.035     Document Type: Article

References (34)

1. Whitley R.J. Herpes simplex virus infection. Semin Pediatr Infect Dis 13 January (1) (2002) 6-11
2. Parr M.B., and Parr E.L. Protective immunity against HSV-2 in the mouse vagina. J Reprod Immunol 36 November (1-2) (1997) 77-92
3. Harandi A.M., Svennerholm B., Holmgren J., and Eriksson K. Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J Gen Virol 82 April (Pt 4) (2001) 845-853
4. Milligan G.N., Bernstein D.I., and Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 160 June (12) (1998) 6093-6100
5. Abu-Raddad L.J., Magaret A.S., Celum C., Wald A., Longini Jr. I.M., Self S.G., et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 3 5 (2008) e2230
6. Koelle D.M., and Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16 January (1) (2003) 96-113
7. Bernstein D.I., and Stanberry L.R. Herpes simplex virus vaccines. Vaccine 17 March (13-14) (1999) 1681-1689
8. Ashkar A.A., Yao X.D., Gill N., Sajic D., Patrick A.J., and Rosenthal K.L. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis 190 November (10) (2004) 1841-1849
9. Harandi A.M., Eriksson K., and Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 77 January (2) (2003) 953-962
10. Ashkar A.A., Bauer S., Mitchell W.J., Vieira J., and Rosenthal K.L. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol 77 August (16) (2003) 8948-8956
11. Pyles R.B., Higgins D., Chalk C., Zalar A., Eiden J., Brown C., et al. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol 76 November (22) (2002) 11387-11396
12. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., and Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 166 March (5) (2001) 3451-3457
13. Tengvall S., Lundqvist A., Eisenberg R.J., Cohen G.H., and Harandi A.M. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J Virol 80 June (11) (2006) 5283-5291
14. Singh M., Chakrapani A., O'Hagan D., and Nanoparticles. microparticles as vaccine-delivery systems. Expert Rev Vaccines 6 October (5) (2007) 797-808
15. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14 December (2) (1991) 195-207 [discussion 8-10]
16. Perez O., Lastre M., Lapinet J., Bracho G., Diaz M., Zayas C., et al. Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine. Infect Immun 69 July (7) (2001) 4502-4508
17. Perez O., Bracho G., Lastre M., Mora N., del Campo J., Gil D., et al. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biol 82 December (6) (2004) 603-610
18. Rodriguez T., Perez O., Menager N., Ugrinovic S., Bracho G., and Mastroeni P. Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery. Vaccine 23 January (10) (2005) 1312-1321
19. Perez O., Lastre M., Cabrera O., del Campo J., Bracho G., Cuello M., et al. New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand J Immunol 66 August-September (2-3) (2007) 271-277
20. Campo J.D., Zayas C., Romeu B., Acevedo R., Gonzalez E., Bracho G., et al. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses. Methods 49 December (4) (2009) 301-308
21. Zayas C., Bracho G., Lastre M., Gonzalez D., Gil D., Acevedo R., et al. Scale up of proteoliposome derived Cochleate production. Vaccine 24 April (Suppl. 2) (2006) S2-94-95
22. del Campo J., Lastre M., Bracho G., Rodriguez T., Gil D., Zayas C., et al. Immunological evaluation of bacterial derived Cochleate and proteoliposome as mucosal adjuvants. Vaccine 24 April (Suppl. 2) (2006) S2-50-51
23. Acevedo R., Callico A., Del Campo J., Gonzalez E., Cedre B., Gonzalez L., et al. Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods 49 December (4) (2009) 309-315
24. Johansson E.L., Wassen L., Holmgren J., Jertborn M., and Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 69 December (12) (2001) 7481-7486
25. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 51 September (1-3) (2001) 21-42
26. Finkelman F.D., Holmes J., Katona I.M., Urban Jr. J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 8 (1990) 303-333
27. Martin R.M., Brady J.L., and Lew A.M. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 212 March (2) (1998) 187-192
28. Parr M.B., and Parr E.L. The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice. Virology 258 June (2) (1999) 282-294
29. Milligan G.N., and Bernstein D.I. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 229 March (1) (1997) 259-268
30. O'Neill L.A.J., and Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7 5 (2007) 353-364
31. Parr M.B., Harriman G.R., and Parr E.L. Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice. Immunology 95 October (2) (1998) 208-213
32. Harandi A.M., Svennerholm B., Holmgren J., Eriksson K., and Interleukin-12. (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J Virol 75 July (14) (2001) 6705-6709
33. Takeda K., and Akira S. TLR signaling pathways. Semin Immunol 16 February (1) (2004) 3-9
34. Barr T.A., Brown S., Mastroeni P., and Gray D. B cell intrinsic MyD88 signals drive IFN-gamma production from T cells and control switching to IgG2c. J Immunol 183 July (2) (2009) 1005-1012